Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||PQR309 + Venetoclax|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|PQR309||PQR 309|bimiralisib||mTOR Inhibitor 51 PI3K Inhibitor (Pan) 37||PQR309 (bimiralisib) is a dual pan-PI3K and mTORC1/2 inhibitor, which blocks PI3K/mTOR signaling, potentially resulting in inhibition of tumor growth (PMID: 29066507).|
|Venetoclax||Venclexta||ABT-199|RG7601|GDC-0199|ABT119||BCL2 inhibitor 17||Venclexta (venetoclax) is a BH3-mimetic that binds to and inhibits BCL2, resulting in increased tumor cell apoptosis (PMID: 26589495, PMID: 25048785). Venclexta (venetoclax) is FDA approved for use in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and in combination with chemotherapy in patients 75 years old or older with newly-diagnosed acute myeloid leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lymphoma||not applicable||PQR309 + Venetoclax||Preclinical - Cell line xenograft||Actionable||In a preclinical study, the combination therapy of PQR309 and Venclexta (venetoclax) led to antitumor activity in lymphoma cells in culture and cell line xenograft models, demonstrating both synergistic and additive effects (PMID: 29066507).||29066507|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|